One in Six. The Only Promising Meth Treatment Works — But Barely.

A longitudinal mediation analysis published on medRxiv in May 2026 digs into why the bupropion-naltrexone combination works for some people with methamphetamine use disorder and not others. The short answer, according to the analysis: depression is the key mediator. Patients whose depressive symptoms decreased during treatment were significantly more likely to reduce or stop methamphetamine use. The implication is that the combination isn’t primarily working on methamphetamine craving in a direct pharmacological sense — it’s working by stabilizing mood, and mood stabilization is what creates the opening for behavioral change.

This matters because the treatment doesn’t work for most people. The ADAPT-2 trial, published in the New England Journal of Medicine in 2021 and conducted by the NIDA Clinical Trials Network, found that bupropion plus naltrexone helped reduce meth use in people with moderate-to-severe methamphetamine use disorder — but only in approximately 1 in 6 patients. That is a modest response rate by any measure. By comparison, buprenorphine for opioid use disorder shows abstinence rates of 40–60 percent at one year in well-designed trials.

The response rate gap reflects something real about the neurobiology of stimulant addiction. Methamphetamine causes more severe and sustained dopaminergic disruption than most other substances. After heavy chronic use, the brain’s dopamine system is compromised in ways that take months to years to recover — reduced receptor density, impaired dopamine production, blunted capacity for reward from ordinary stimuli. The withdrawal experience from methamphetamine is less acutely dangerous than opioid or benzodiazepine withdrawal in the physical sense, but psychologically it is among the most difficult: a flatness of affect, inability to feel pleasure, cognitive fog, and crushing low-grade depression that can persist for months. What the mediation analysis suggests is that the bupropion-naltrexone combination works by addressing that depression component — bupropion being, fundamentally, an antidepressant with stimulant-like properties — and that the patients for whom it works are those whose depression is responsive to bupropion’s mechanism.

There are currently zero FDA-approved medications for any stimulant use disorder — cocaine, methamphetamine, or prescription stimulant misuse. The bupropion-naltrexone combination is being used off-label. The Phase 3 trial (NCT06233799, 360 participants, UCSD-led) that would support an FDA application is currently running, with primary completion targeted for October 2026. If the Phase 3 results replicate ADAPT-2’s findings — even at a 1-in-6 response rate — the regulatory case for approval is not straightforward. The FDA will have to determine whether a treatment that works for roughly 16 percent of patients, with no alternative approved options and a substantial disease burden, clears the efficacy bar.

That is the actual question at stake. Not whether 1 in 6 sounds like a good number — it doesn’t — but whether 1 in 6 is better than nothing in a treatment landscape where “nothing” is currently the alternative for 1.4 million people with methamphetamine use disorder in the United States. The treatment-recovery answer to that question is almost certainly yes. The FDA’s answer depends on how it weighs need against marginal benefit.

The mediation findings point toward a more targeted approach: rather than treating methamphetamine use disorder as a single diagnostic entity, clinical practice might identify patients with co-occurring depressive symptoms as the subgroup most likely to respond to this combination. Precision medicine for addiction pharmacotherapy — using biomarkers or clinical profiles to match patients to medications most likely to work for them — is still early, but this kind of mediation analysis is the intellectual foundation on which it’s being built.

The stimulants treatment gap is the largest in addiction pharmacology. It should be receiving proportional research investment.

---

Follow stimulants coverage and treatment and recovery for updates on the Phase 3 trial completion, expected October 2026.